ISDA

Entry Detail

PDB ID:

7D5L

Keywords:

Title:

Discovery of BMS-986144, a Third Generation, Pan Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

Biological Source:

Source Organism:

Hepacivirus C

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2020-09-26

Release Date:

2020-12-16

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.15 Å

R-Value Free:

0.23

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:NS3/4A Protease
Chain IDs:A, B, C (auth: D), D (auth: E)
Chain Length:219
Number of Molecules:4
Biological Source:Hepacivirus C

UniProt ID:A0A0B4WYC6 Pfam ID:PF02907

Ligand Molecules

GXO

Primary Citation

Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.

Sun, L.Q, Mull, E, D'Andrea, S, Zheng, B, Hiebert, S, Gillis, E, Bowsher, M, Kandhasamy, S, Baratam, V.R, Puttaswamy, S, Pulicharla, N, Vishwakrishnan, S, Reddy, S, Trivedi, R, Sinha, S, Sivaprasad, S, Rao, A, Desai, S, Ghosh, K, Anumula, R, Kumar, A, Rajamani, R, Wang, Y.K, Fang, H, Mathur, A, Rampulla, R, Zvyaga, T.A, Mosure, K, Jenkins, S, Falk, P, Tagore, D.M, Chen, C, Rendunchintala, K, Loy, J, Meanwell, N.A, McPhee, F, Scola, P.M.Show

J.Med.Chem. 63 14740 14760 (2020)

PMID: 33226226 DOI: 10.1021/acs.jmedchem.0c01296

Abstact

The discovery of a pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor based on a P1-P3 macrocyclic tripeptide motif is described. The all-carbon tether linking the P1-P3 subsites of 21 is functionalized with alkyl substituents, which are shown to effectively modulate both potency and absorption, distribution, metabolism, and excretion (ADME) properties. The CF3Boc-group that caps the P3 amino moiety was discovered to be an essential contributor to metabolic stability, while positioning a methyl group at the C1 position of the P1' cyclopropyl ring enhanced plasma trough values following oral administration to rats. The C7-fluoro, C6-CD3O substitution pattern of the P2* isoquinoline heterocycle of 21 was essential to securing the targeted potency, pharmacokinetic (PK), and toxicological profiles. The C6-CD3O redirected metabolism away from a problematic pathway, thereby circumventing the time-dependent cytochrome P (CYP) 450 inhibition observed with the C6-CH3O prototype.

Legend

Protein

Chemical

Disease

Primary Citation of related structures